Abschlussbericht zum Modellprojekt des BMA "Beschäftigungs-/Integrationsprojekte (-firmen, -betriebe, -abteilungen)": A. Zusammenfassungen und Empfehlungen; B. Abschlußbericht

"Beschäftigungs-/Integrationsprojekte (-firmen, -betriebe, -abteilungen) zur Eingliederung schwerbehinderter Menschen in das Arbeitsleben." Abschlussbericht der wissenschaftlichen Begleitung zur Arbeit der Modellprojekte im Auftrag des Bundesministeriums für Arbeit und Sozialordnung; Teil A: Zusammenfassungen und Empfehlungen, Teil B: Abschlussbericht (Begleitforschung)

Continuous glucose monitoring: A training programme for all age groups

Optimal usage of continuous glucose monitoring (CGM) requires adequate preparation and training. Patients using a CGM system without special training often do not achieve their intended improvement of metabolic control. Some stop using the system due to disappointing results. For this reason a structured training programme called ‘SPECTRUM’ was developed in Germany to ensure a high-quality standard for the initiation of CGM systems. This programme is suitable for patients of all age groups and is applicable to all CGM systems and all forms of insulin therapy. Structured curricula (adults, parents of young children, adolescents) were developed enabling diabetes centres with less experience to offer comprehensive CGM training. Key requirements of SPECTRUM were (1) independent from manufactures and (2) product-neutrality enabling certification for reimbursement after formal evaluation within the framework of a large clinical trial. SPECTRUM was published in January 2016 in German and translations into other languages are planned

SPECTRUM: A Training and Treatment Program for Continuous Glucose Monitoring for All Age Groups

Background: Optimal usage of continuous glucose monitoring (CGM) requires adequate training of the users. Providing patients with a CGM system without such a training usually doesn’t lead to the intended improvement in metabolic control. Methods: In Germany we developed a structured training program (“SPECTRUM”) to ensure a high quality standard for the use of CGM systems. Results: This program is suitably for patients of all age groups and is applicable to all CGM systems and all forms of insulin therapy. A curriculum was also developed so that training centers with less experience with CGM could become capable of offering comprehensive CGM training. Conclusions: We believe that usage of such a program can be an important step forward in achieving more widespread acceptance and use of CGM systems. Translations in other languages and evaluation with a controlled clinical trial are planned

Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML

The mechanism underlying cell type-specific gene induction conferred by ubiquitous transcription factors as well as disruptions caused by their chimeric derivatives in leukemia is not well understood. Here we investigate whether RNAs coordinate with transcription factors to drive myeloid gene transcription. In an integrated genome-wide approach surveying for gene loci exhibiting concurrent RNA- and DNA-interactions with the broadly expressed transcription factor RUNX1, we identified the long noncoding RNA LOUP. This myeloid-specific and polyadenylated lncRNA induces myeloid differentiation and inhibits cell growth, acting as a transcriptional inducer of the myeloid master regulator PU.1. Mechanistically, LOUP recruits RUNX1 to both the PU.1 enhancer and the promoter, leading to the formation of an active chromatin loop. In t(8;21) acute myeloid leukemia, wherein RUNX1 is fused to ETO, the resulting oncogenic fusion protein RUNX1-ETO limits chromatin accessibility at the LOUP locus, causing inhibition of LOUP and PU.1 expression. These findings highlight the important role of the interplay between cell type-specific RNAs and transcription factors as well as their oncogenic derivatives in modulating lineage-gene activation and raise the possibility that RNA regulators of transcription factors represent alternative targets for therapeutic development